UBS Group Lowers Kura Oncology (NASDAQ:KURA) Price Target to $14.00

Kura Oncology (NASDAQ:KURA) had its price target lowered by UBS Group from $27.00 to $14.00 in a report released on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s target price would indicate a potential upside of 85.55% from the stock’s current price.

Several other research analysts have also weighed in on the company. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Scotiabank cut their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. BTIG Research cut shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Price Performance

Shares of NASDAQ KURA traded up $0.18 during mid-day trading on Thursday, reaching $7.55. The company had a trading volume of 290,880 shares, compared to its average volume of 1,567,358. The company has a 50-day moving average price of $8.04 and a two-hundred day moving average price of $13.51. The stock has a market cap of $586.73 million, a PE ratio of -3.18 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, equities analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. Suvretta Capital Management LLC boosted its holdings in Kura Oncology by 8.2% during the third quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock valued at $149,535,000 after purchasing an additional 583,155 shares in the last quarter. Vanguard Group Inc. grew its position in Kura Oncology by 14.6% in the fourth quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company’s stock valued at $41,973,000 after acquiring an additional 615,211 shares during the period. RA Capital Management L.P. acquired a new position in Kura Oncology during the fourth quarter worth $38,769,000. Millennium Management LLC boosted its stake in shares of Kura Oncology by 180.1% in the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock valued at $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Kura Oncology by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock worth $34,798,000 after purchasing an additional 41,535 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.